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Purpose. To investigate the oncological outcome and survival of patients following a conservative approach on the portal-
mesenteric axis, in an intraoperative ultrasound-selected group of pancreatoduodenectomy (PD), performed on patients with
primary resectable with vascular contact (prVC) pancreatic ductal adenocarcinoma (PDAC). Methods. A consecutive series of
patients who underwent PD for PDAC at our tertiary care center, between 2008 and 2017, were reviewed. A total of 156 PDs
and 88 total pancreatectomies were performed during the study period, including 35 vascular resections. We identiﬁed a group
of 40 (25.6%) patients with prVC-PDAC in whom after checking the feasibility with intraoperative ultrasound, we were able to
perform PD by separation of the tumor from the portomesenteric axis avoiding vascular resection, without residual macroscopic
disease (no vascular resection, nvrPD), and compared this group, using case-matched methodology, with the standard PD (sPD)
group of primary resectable without vascular contact- (prwVC-) PDAC. Results. The median follow-up was 28.5± 23.2 months
in the sPD group and 23.8± 20.8 months in the nvrPD group (p = 0 35). Isolated local recurrence rate was 2/40 (5%) in both
groups. Additionally, there were no statistical diﬀerences in the systemic progression of the disease (42.5% sPD vs. 45% nvrPD,
p = 0 82) or local plus synchronous systemic disease rates (2.5% sPD vs. 7.5% nvrPD, p = 0 30). The median survival was 22
months for the sPD group and 23 months for the nvrPD group, p = 0 86. The overall survival was similar in the two groups
(1 y: 76.3% sPD vs. 70.0% nvrPD; 3 y: 35.6% vs. 31.6%; and 5 y: 28.5% vs. 25.3%; p = 0 80). Conclusions. PD without vascular
resection can be considered safe and oncologically acceptable in selected patients with preoperative diagnosis of prVC-PDAC.
The poor prognosis of PDAC is related to the aggressive biology and systemic spread of the tumor, rather than the local
control of the disease.
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most biologically aggressive neoplasms characterized by poor
prognosis with a mortality rate which currently ranks ﬁfth
in the list of cancer-related deaths. Surgical management
remains the primary treatment, but resection is possible only
in 15 to 20% of patients [1]. Approximately 65% of pancre-
atic tumors involve the pancreatic head. While patients with
body or pancreatic tail cancer present usually with metastatic
disease, lesions arising in the pancreatic head usually present
with jaundice or symptoms related to duodenal obstruction.
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Consequently, patients with pancreatic head tumors may
obtain improved survival from early diagnosis and treatment.
In these cases, whenever possible, an R0 resection margin is
associated with a 5-year survival rate of 20% in some reports.
Because the pancreatic head is anatomically closely related to
major arteries and veins, in 40% of patients, cancer involves
one or more major vascular structures at the time of diagno-
sis [2]. The concept of borderline resectable pancreatic can-
cer [3] and the staging system proposed by the consensus
statement of the Society of Abdominal Radiology and the
American Pancreatic Association [4, 5] underlines the close
relationship between the critical visceral vasculature and the
local spread of the disease. The primary portal-mesenteric
axis en bloc resection during pancreatoduodenectomy (PD)
is considered a safe approach in experienced high-volume
centers with acceptable morbidity and mortality and favour-
able prognosis compared to unresectable disease. However,
the beneﬁt in terms of improved disease-free survival by this
aggressive major surgical resection remains unproven.
Thepresent studywas designed to investigate the oncolog-
ical outcome (local/distant recurrence rate) and patients’ sur-
vival after a conservative approach on the portal-mesenteric
venous axis (PMA) in an intraoperative ultrasound- (IOUS-)
selected group of PDs, in patients with primary resectable
with vascular contact- (prVC-) PDAC.
2. Materials and Methods
From January 2008 to December 2017, 433 pancreatic resec-
tions were performed at the General Surgery Unit of the
University of Pisa, of which a total of 156 were PDs for
PDAC: 135 without vascular resection (VR) and 21 with
VR. Eighty-eight patients underwent a total pancreatectomy,
of which 51 for PDAC and 14 VR.
In this period, in our institution, primary pancreatic
resection was contraindicated only when metastatic disease
and invasion of the superior mesenteric or celiac artery were
identiﬁed by preoperative imaging. PMA inﬁltration was not
considered a contraindication for primary resection.
An intraoperative ultrasound (IOUS) with high-
frequency probe (12-5MHz, Intraoperative Biplane, BK
Medical APS, Peabody, MA, USA) in order to check the
relationship between the tumor and the PMA and SMA
and to exclude occult liver metastasis was routinely per-
formed in all patients undergoing PD. In case of the US sign
of inﬁltration of PMA, we proceeded with an en bloc resec-
tion of the tumor with the tract of the vein involved, while
for cases with a cleavage plane between the tumor and the
PMA detected by ultrasound, we peeled oﬀ the vein from
the tumor through a macroscopic tumor-free plane.
Preoperative workup included anamnestic collection,
physical examination, blood exams, abdominal ultrasound
(US), computed tomography (CT), magnetic resonance
(MRI), and, depending on the case, other diagnostic
methods, such as contrast-enhanced ultrasound (CEUS),
endoscopic ultrasonography (EUS), and positron emission
tomography (PET).
Preoperative biliary drainage was performed when biliru-
bin blood level was higher than 20mg/dl. Patients underwent
neoadjuvant therapy, when considered locally advanced at
the diagnostic imaging.
Decisions about clinical management involved a multi-
disciplinary consultation between surgeons, oncologists,
radiologists, and radiotherapists. Patients’ data were stored
in a dedicated institutional database.
For the present study, the grade of PMA invasion and the
types of PDAC regarding tumor resectability (resectable,
borderline resectable, locally advanced, and metastatic
disease) were assigned retrospectively according to the
National Comprehensive Cancer Network (NCCN) classiﬁ-
cation system [6] and to the International consensus on the
deﬁnition and criteria of borderline resectable pancreatic
ductal adenocarcinoma 2017 [7].
We identiﬁed a group of 40 patients with primary
resectable disease with venous contact- (prVC-) PDAC, in
whom, after checking the feasibility with IOUS, the vein
had been peeled oﬀ the tumor without leaving macroscopic
residual disease, avoiding a vascular resection (nvrPD
group). We compared this group with a control group of
40 patients treated with a standard PD (sPD) for primary
resectable without vascular contact- (prwVC-) PDAC. The
control group was selected using a one-to-one case-
matched methodology from the prospectively collected
institutional database, where each patient of the nvrPD group
was matched with a patient operated for prwVC-PDAC,
using the following criteria: age, tumor size, grading, stage,
and adjuvant therapy.
In these two groups, we evaluated diﬀerences in perioper-
ative surgical results, local/distant recurrence, and survival.
Prospectively collected details regarding pre-, intra-, and
postoperative course and follow-up of patients of the two
groups were retrospectively analysed and compared.
Preoperative and operative data included age, sex, BMI,
ASA score, and operative time. Postoperative data included
the length of hospital stay, postoperative morbidity (accord-
ing to the Clavien-Dindo classiﬁcation) [8], reintervention
rate, and 30-day mortality. The medical complications
recorded were pulmonary or urinary tract infections, cardiac
complications, and neurological complications. The surgical
complications included intra-abdominal ﬂuid collections,
surgical site infections, postoperative pancreatic ﬁstula,
digestive, and biliary or intraperitoneal hemorrhage. Postop-
erative pancreatic ﬁstula (POPF) was deﬁned and classiﬁed
using the 2016-Revised International Study Group on
Pancreatic Surgery classiﬁcation (ISGPSc) [9]. Pathological
data included the stage of pancreatic cancer, number of
harvested lymph nodes, lymph node status, perineural space
invasion, vascular space inﬁltration, vascular bed inﬁltration
(medial pancreatic margin), and resection margin status.
Pathological data included the stage of pancreatic
cancer according to the AJCC/TNM classiﬁcation (8th
edition) and the residual tumor classiﬁcation (R0, free
tumor margin> 1mm; R1, free tumor margin if <1mm
or microscopic residual tumor; and R2; macroscopic residual
tumor) [10, 11].
During the follow-up, data was collected on adjuvant
therapy; local or systemic recurrence; the 1-, 3-, and 5-year
overall survival (OS); and the disease-free survival (DFS)
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rate. The OS was deﬁned as the length of time from the sur-
gical resection of the pancreatic adenocarcinoma to the
patient’s death (last follow-up). Similarly, the DFS was
deﬁned as the time from the surgical resection to the diagno-
sis of recurrence (symptoms, radiological evidence, and/or
pathological conﬁrmation).
2.1. Statistical Analysis. For the data analysis, the χ2 test was
used to deﬁne associations between categorical factors and
surgical groups. Continuous variables with normal distribu-
tion are expressed as the mean± standard deviation (SD)
and compared using Student’s t-test, with a signiﬁcance
being set at p < 0 05. Variables with an abnormal distribution
are expressed as the median and compared using the
Wilcoxon test. Survival was compared using the Kaplan–
Meier curves and log-rank test. The statistical analysis was
performed using SPSS (Statistical Production and Service
Solution for Windows, SPSS Inc., Chicago, IL, USA) and
STATA version 13 (STATA Corp., TX, USA).
3. Results
Demographic characteristics summarized in Table 1 showed
no signiﬁcant diﬀerences in clinical features between the two
groups. The mean overall operative time (OT) was similar in
both groups (435.9± 93.8 in the sPD group vs. 429.4± 86.1 in
the nvrPD group, p = 0 75). Postoperative data (Table 2)
showed no diﬀerence in the median length of postoperative
stay between the two groups:15.0 days vs. 17.0 days for the
sPD and nvrPD groups, respectively (p = 0 11). The overall
postoperative complication rate was similar in both groups,
occurring in 16 patients (40.0%) in the sPD group and in
22 patients (55.0%) in the nvrPD group (p = 0 18). Medical
complications occurred in 10 cases (25%) and in 17 cases
Table 1: Patient characteristics and operative data.
sPD group (n = 40) nvrPD group (n = 40) p value
Mean age, year (range) 68.0± 11.1 (42-86) 68.8± 11.0 (46-92) 0.76
Male, n (%) 25 (62.5%) 23 (57.5%)
0.65
Female, n (%) 15 (37.5%) 27 (32.5%)
Mean body mass index, kg/m2 (range) 25.0± 4.1 (16.1-39.0) 28.8± 5.0 (14.7-43.6) 0.99
ASA score, n (%)
0.49
ASA I 1 (2.5%) 0
ASA II 10 (25%) 6 (15%)
ASA III 24 (60%) 28 (70%)
ASA IV 5 (12.5%) 6 (15%)
Neoadjuvant therapy, n (%) 0 0 1
Mean overall operative time, min (range) 435.9± 93.8 (280-745) 429.4± 86.1 (300-700) 0.75
Table 2: Postoperative and pathological data.
sPD group (n = 40) nvrPD group (n = 40) p value
Median length of postoperative stay, days [Q1–Q3] 15 (12-23) 17 (12-29.5) 0.11
Overall complications, number of patients (%) 16 (40%) 22 (55%) 0.18
Clavien-Dindo classiﬁcation of postoperative complications
0.69
Grade I 2 (5%) 5 (12.5%)
Grade II 7 (17.52%) 10 (25%)
Grade III 4 (10%) 3 (7.5%)
Grade IV 2 (5%) 3 (7.5%)
Grade V 1 (2.5%) 1 (2.5%)
Medical complications, n (%) 10 (25%) 17 (42.5%) 0.10
2016 ISGPS POPF, n (%) 3 (7.5%) 3 (7.5%) 1
Biochemical leak 2 (5%) 4 (10%)
0.59Grade B POPF 1 (2.5%) 0
Grade C POPF 2 (5%) 3 (7.5%)
Surgical complications, n (%) 6 (15%) 5 (12.5%) 0.75
Reintervention, n (%) 4 (10%) 3 (7.5%) 0.69
Mortality 1 (2.5%) 1 (2.5%) 1
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(42.5%) in the sPD and nvrPD groups, respectively (p = 0 10).
Pancreatic ﬁstula (according to the 2016-revised ISGPSc of
POPF) developed in 3/40 patients (7.5%) in both groups:
one grade B POPF (2.5%) and 2 (5%) grade C POPF in the
sPD group and 3 (7.5%) grade C POPF in the nvrPD group;
p = 0 55. Surgical complications occurred in 6 patients (15%)
in the sPD group and in 5 patients (12.5%) in the nvrPD
group (p = 0 75). The surgical complications in the sPD
group were digestive hemorrhage (n = 2), bleeding associ-
ated with POPF grade C (n = 2), parietal hematoma (n = 1),
and obstruction of the gastrointestinal anastomosis (n = 1).
In the nvrPD group, surgical complications were digestive
hemorrhage (n = 2) and bleeding associated with POPF
grade C (n = 3). Digestive hemorrhage was treated with
endoscopic intervention in all cases of both groups. Reinter-
vention was required in 4 patients (10%) of the sPD group
(2 grade C POPF, 1 parietal hematoma, and one gastroin-
testinal anastomosis obstruction) and in 3 patients (7.5%)
of the nvrPD group (3 grade C POPF, p = 0 69). Postoper-
ative mortality rate was 2.5% (1/40 cases) in both groups.
Pathological ﬁndings are summarized in Table 3. No diﬀer-
ences were reported between the two groups in terms of the
stage of the disease, perineural and vascular bed inﬁltration.
A mean of 28.4± 13.4 lymph nodes per patient was harvested
in the sPD group versus 31.5± 14.1 in the nvrPD group
(p = 0 32). The lymph nodes were positive in 29/40 cases
(72.5%) in the sPD vs. 30/40 cases (75%) in the nvrPD
(p = 0 80).
The median follow-up was 28.5± 23.2 months in the sPD
group and 23.8± 20.8 months in the nvrPD group (p = 0 35).
No patients in the two groups underwent neoadjuvant
therapy because of primary resectable PDAC. In the sPD
group, 21 patients (52.5%) vs. 20 patients (50%) in the nvrPD
group received adjuvant therapy (p = 0 82). The disease-free
survival (DFS) with the Kaplan–Meier method is shown in
Figure 1. Isolated local recurrence was reported in 2/40 cases
(5%) in both groups. No statistically signiﬁcant diﬀerence in
systemic progression or combined local and synchronous
systemic disease rate was reported between the two groups:
17/40 cases (42.5%) in the sPD group vs. 18/40 case (45%)
in the nvrPD group (p = 0 82) and 1/40 cases (2.5%) in the
sPD group vs. 3/40 cases (7.5%) in the nvrPD group
(p = 0 30, Table 4). Survival analysis using the Kaplan–Meier
Table 3: Pathological data.
sPD group (n = 82) nvrPD group (n = 34) p value
Stage, n (%)
0.79
Ia 1 (2.5%) 2 (5%)
Ib 0 1 (2.5%)
IIa 8 (20.0%) 7 (17.5%)
IIb 29 (72.5%) 29 (72.5%)
III 1 (2.5%) 2 (5%)
Perineural space inﬁltration, n (%) 27 (67.5%) 33 (82.5%) 0.12
Vascular space inﬁltration, n (%) 12 (30%) 14 (35%) 0.63
Vascular bed inﬁltrations, n (%) 3 (7.5%) 5 (12.5%) 0.46
Mean lymph node harvest, n (range) 28.4± 13.4 (10-84) 31.5± 14.1 (9-69) 0.32
Patient with positive lymph nodes, n (%) 29 (72.5%) 30 (75%) 0.80
Grading, n (%)
0.55
G1 1 (2.5%) 2 (5%)
G2 33 (82.5%) 29 (72.5%)
G3 6 (15%) 9 (22.5%)
R-status, n (%)
0.69R0 37 (92.5%) 36 (90%)
R1 3 (7.5%) 4 (10%)
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Figure 1: Disease-free survival (DFS) of the sPD and nvrPD groups.
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method is shown in Figure 2. The median survival was 22
months for the sPD group and 23 months for the nvrPD
group (p = 0 80). No diﬀerence in the overall survival was
observed between the two groups: 1-year overall survival rate
was 76.3% in the sPD group vs. 70.0% in the nvrPD
group; 3-year overall survival rate was 35.6% in the sPD
group vs. 31.6% in the nvrPD group; and 5-year overall
survival was 28.5% in the sPD group vs. 25.3% in the
nvrPD group (p = 0 81).
4. Discussion
The pancreatic head is closely related to major arteries and
veins, which are involved at the time of diagnosis in 40%
of pancreatic ductal adenocarcinoma [2, 12]. According to
the National Comprehensive Cancer Network (NCCN)
guidelines, pancreatic cancer with superior mesenteric vein
(SMV) and/or portal vein (PV) involvement greater than
180 degrees is considered borderline resectable unless the
portal venous ﬂow can be restored [3]. Several reports have
shown similar short- and mid-term survival of patients with
vein resection compared to patients treated with standard
PD; speciﬁcally, Yekebas et al. [13] and Tseng et al. [14]
did not report any diﬀerence in postoperative morbidity,
mortality, and survival rate between the two groups. As a
result of these reports, the surgical treatment in high-
volume centers consists of mesenteric root mobilization
and primary vascular resection en bloc, including cases of
unilateral contact on preoperative imaging. The treatment
includes all the true positive cases but overtreats many
patients in whom histology of the excised specimen reveals
only juxtavascular peritumoral inﬂammatory adherence
rather than actual vascular inﬁltration [15]. Although feasi-
ble and safe, vascular resection is associated with increased
perioperative risks, with increased morbidity associated with
venous reconstruction [16, 17]. In patients with jaundice,
portal clamping may further impair liver function [18].
The development of pancreatic ﬁstula close to the suture line
may promote thrombosis or pancreatic ﬁstula-associated
hemorrhage because the vascular resection and revasculari-
zation increase the likelihood of vessels being eroded by
any pancreatic leak [19]. Furthermore, in patients treated
with a total splenopancreatectomy, the compromised gastric
venous drainage may necessitate a subtotal or total gastrec-
tomy with increased postoperative morbidity [20]. Hence,
some reports have raised doubts on the beneﬁt of portal/
mesenteric vein resection and have indicated that patients
do not obtain any survival beneﬁt after PV/SMV/PMA
resection [14, 21, 22]. In fact, Roch et al. reported that vascu-
lar resection increased the 90-day mortality and that the ves-
sel wall invasion does not represent a speciﬁc prognostic
factor of overall survival because patients with and without
vein resection obtained comparable overall survival rates at
1, 3, and 5 years. Indeed, the same authors report a higher
rate of recurrence in the PMA resection group, probably
because survival in these patients is largely due to aggressive
tumor biology [23]. Zhou et al. in a meta-analysis including
19 studies found no diﬀerences in terms of overall survival
between vascular and no vascular resection PDs. They also
concluded that these patients’ higher local recurrence did
not materially contribute to poor survival, since this death
was largely due to the systemic progression of the disease
[24]. Preoperative staging can provide useful information
on the relationship between the pancreatic tumor and the
vascular wall to assist in planning the surgical resection.
Multidetector computed tomography (MDCT) has provided
the most accurate assessment of vascular involvement show-
ing excellent sensitivity (100%) and speciﬁcity (72%) and
high positive predictive value (89%) [3]. Al-Hawary et al.
published a consensus statement of the Society of Abdomi-
nal Radiology and the American Pancreatic Association on
preoperative cross-sectional imaging evaluation of tumor
involvement of PMA [4]. The probability of vascular inva-
sion is related to the contact of the tumor with the vessel.
In a study by Springett and Hoﬀe, the probability of vascular
invasion was increased to 40%, 80%, and 100% when the
tumor had ≤180° contact, >180° contact, and 360°contact,
respectively [25]. Moreover, venous caliber change at imag-
ing is related with venous wall invasion as reported by
Nakao et al. who demonstrated an absence of venous
Table 4: Follow-up data.
sPD group
(n = 40)
nvrPD group
(n = 40) p value
Adjuvant therapy (n, %) 21 (52.5%) 20 (50%) 0.82
Isolated local recurrence
(n, %)
2 (5%) 2 (5%) 1
Systemic progression
(n, %)
17 (42.5%) 18 (45%) 0.82
Local and systemic disease
(n, %)
1 (2.5%) 3 (7.5%) 0.30
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Figure 2: Overall survival (OS) of the sPD and nvrPD groups.
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invasion on pathologic examination of resected specimens in
patients without a radiographic appearance of vascular
involvement while vascular invasion was revealed by patho-
logic examination in 51%, 74%, and 93% of patients with
radiographic unilateral portal vein narrowing, bilateral por-
tal vein narrowing, and complete portal vein obstruction
with venous collateral formation, respectively [15]. Further-
more, the ability of CT to predict that vein resection is nec-
essary approximates to 40% [26]. For these reasons, if the
borderline resectable tumor with PMA invasion necessitates
vascular resection to achieve a potentially curative resection,
the focal contact between the neoplasm and the vascular wall
is best considered a “black zone,” because at histopathologi-
cal examination, the resected vessel is subsequently con-
ﬁrmed to be inﬁltrated by tumor in only 20-30% of cases
[27]. In this respect, the severe desmoplastic reaction
induced by pancreatic cancer contributes to the diﬃculty
in the diﬀerentiation between adhesion and true vascular
invasion. Thus, in this subgroup of patients, primary vascu-
lar resection may not be necessary. This diﬃculty in preop-
erative evaluation is related to the radiological deﬁnition of
the vascular contact that diﬀers from the pathological exam-
ination of the resected specimen.
The objective of the present study was to evaluate if the
dissection of the tumor from the PMA in prVC could have
similar surgical and oncologic outcome of a standard PD
allowing surgeons to manage this situation without perform-
ing a vascular resection. In this single-center experience, a
series of 40 prVC-PDAC were retrospectively compared with
a comparable group of prwVC-PDAC, using a case-matched
methodology, treated with standard PD. The use of IOUS
proved to be very useful in the management of this prVC
group as it enabled the deﬁnition of the limit of the PDAC
and enabled diﬀerentiation between PMA involvements by
the tumor from an inﬂammatory peritumoral process,
enabling US-guided peeling with the preservation of PMA.
The reported literature supports the usefulness of intraoper-
ative ultrasound specially in identifying resectable head pan-
creatic lesions without inﬁltration of PMA [28, 29]. In fact,
the adenocarcinoma appears as a hypoechogenic mass at
IOUS, the margins and size of the lesion are more clearly vis-
ible and the relationship between the tumor and the critical
vessels can be better evaluated.
Our study has demonstrated comparable oncologic
results between the sPD and the nvrPD groups. Signiﬁcantly,
local recurrence was not higher in patients who had preser-
vation of the vascular wall. Moreover, according to Zhou
et al. who reported data that indicates that systemic pro-
gression is the leading cause of patients’ death [24], we
observed that the most important factor inﬂuencing long-
term survival was the disease progression represented by
peritoneal spread or hepatic metastasis. In fact, the patients’
survival seems to be related to the aggressive biological
behavior of the tumor, rather progressive local disease,
although adequate resection to achieve local control remains
important, but does not inﬂuence materially patient survival.
In our opinion, the execution of a standard PD without
vascular resection in some of these patients reduces the oper-
ative time, the length of hospital stays, and the morbidity
without compromising clinical oncological outcome and
overall survival.
The present study has some limitations, the ﬁrst being
related to its retrospective nature which inevitably raises pos-
sible selection bias. Secondly, the results of the prVC group
could be overestimated as we did not include patients who
underwent tangential or end-to-end vascular resection. How-
ever, the study underlines the importance of the intraopera-
tive evaluation with US to speciﬁcally assess the extent of
vascular and indeed the presence of vascular involvement
to avoid the need for vascular resection during PD. In addi-
tion, to the best of our knowledge, this remains the ﬁrst series
comparing prwVC-PDAC and “no vascular resection”
prVC-PDAC in a relatively large cohort, although we admit
that further studies are needed to conﬁrm the results of the
present study.
5. Conclusion
PD without VR is a surgical approach that can be considered
safe and oncologically acceptable in selected patients with
preoperative prVC-PDAC. The poor prognosis of this dis-
ease is related to the aggressive biology and systemic spread
of the tumor, rather than its local control. The present study
does not support the need for vascular resection in all
patients with prVC-PDAC.
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